½ÃÀ庸°í¼­
»óǰÄÚµå
1649513

¾à¹° ¿ëÃâ ½ºÅÙÆ® ½ÃÀå : ¿¹Ãø(2025-2030³â)

Drug Eluting Stent Market - Forecasts from 2025 to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Knowledge Sourcing Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 147 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¾à¹° ¿ëÃâ ½ºÅÙÆ® ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È CAGR 8.20%·Î ¼ºÀåÇÏ¿© 2025³â 114¾ï 9,900¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 170¾ï 4,900¸¸ ´Þ·¯·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾à¹°¿ëÃâ ½ºÅÙÆ®´Â ¾à¹°ÀÌ ºÎÂøµÈ ±Ý¼Ó ¹Ý°æ¼º °ü»óµ¿¸Æ ÀåÄ¡·Î, ÇùÂøÀ̳ª µ¿¸ÆÆó¼âÀÇ Àç¹ßÀ» ¹æÁöÇϱâ À§ÇØ ¾à¹°À» ¼­¼­È÷ ¹æÃâÇÒ ¼ö ÀÖ½À´Ï´Ù. ÃÖ±Ù ½ºÅÙÆ® ¼³°è ¹× Àü´Þ ±â¼úÀÇ Çõ½ÅÀº º¹ÀâÇÑ º´º¯¿¡¼­µµ ÀçÇùÂø·üÀ» Å©°Ô °¨¼Ò½ÃÄÑ ÃÊ±â ¹× Èıâ Ç÷ÀüÁõ ¹ß»ý·üÀ» °¨¼Ò½Ãų °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ³ëÀÎ Àα¸°¡ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ¾à¹°¿ëÃâ ½ºÅÙÆ® ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ³ë³âÃþÀº Ç÷°ü ÁúȯÀ» ¾ÎÀ» °¡´É¼ºÀÌ ³ô±â ¶§¹®¿¡ ¾à¹° ¿ëÃâ ½ºÅÙÆ®¿Í °°Àº È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, ¾É¾Æ¼­ »ýȰÇÏ´Â »ýȰ½À°ü°ú ½Ä½À°üÀÇ º¯È­·Î ÀÎÇØ µ¿¸Æ¿¡ ÇöóÅ©°¡ ½×ÀÌ´Â µ¿¸Æ°æÈ­ÁõÀÇ ¹ßº´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ µ¿¸Æ°æÈ­Áõ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¾à¹° ¿ëÃâ ½ºÅÙÆ® ½ÃÀåÀÇ ÃËÁø¿äÀÎ

  • ±â¼úÀÇ ¹ßÀü : Ç¥ÁØ Ç÷°ü¼ºÇü¼ú¿¡¼­ ¾à¹° ¿ëÃâ ½ºÅÙÆ®(DES)·ÎÀÇ ÀüȯÀº Ä¡·á ¿É¼ÇÀÇ Å« Áøº¸¸¦ ÀǹÌÇÕ´Ï´Ù. ½ºÅÙÆ®¿¡ Á÷Á¢ ¾à¹°À» ÁÖÀÔÇÏ´Â ÀÌ ÃÖ¼Òħ½ÀÀû Á¢±Ù¹ýÀº Ç÷°ü ºÎ´ã °¨¼Ò, ȸº¹ ½Ã°£ ´ÜÃà, ÇÕº´Áõ À§Çè °¨¼Ò µî ¸¹Àº ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, Orsiro MissionÀº ¾à¹°À» Ç¥Àû µ¿¸Æ¿¡ Á÷Á¢ Àü´ÞÇÏ¿© ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö Àִ ȹ±âÀûÀÎ ±â¼ú Çõ½ÅÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀÌ ¼º°øÀûÀ¸·Î µµÀԵǸé ÀÇ·á Àü¹®°¡µéÀÌ µ¿¸Æ Áúȯ¿¡ ´ëÇÑ º¸´Ù È¿°úÀûÀÌ°í ´ú ħ½ÀÀûÀÎ Ä¡·á¹ýÀ» ã°Ô µÇ¸é¼­ ½ÃÀå Ȱ¼ºÈ­°¡ ÃËÁøµÉ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

Áö¸®Àû Àü¸Á

  • ºÏ¹Ì°¡ ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»ó: ¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì´Â ¾à¹° ¿ëÃâ ½ºÅÙÆ® ½ÃÀå¿¡¼­ Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº ÀÌ Áö¿ªÀÇ À¯¸®ÇÑ »óȯ Á¤Ã¥°ú µ¿¸Æ °ü·Ã ÁúȯÀÇ ¹ß»ý·ü Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ, 2023³â 2¿ù¿¡ ¹ßÇ¥µÈ Journal of the American College of Cardiology¿¡ µû¸£¸é, ¹Ì±¹ ³» Á׻󵿸ưæÈ­¼º ½ÉÇ÷°üÁúȯÀÇ ¹ßº´·üÀº 2023³â 2¿ù¿¡ ¹ßÇ¥µÉ 10³â ¿¹Ãø À§ÇèÀÌ ³ôÀº »ç¶÷ 1,000¸í´ç 2.60¸íÀÎ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ Åë°è´Â ¾à¹° ¿ëÃâ ½ºÅÙÆ®¿Í °°Àº È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖÀ½À» °­Á¶ÇÕ´Ï´Ù.

°í·ÉÈ­ »çȸ¿¡¼­´Â °ü»óµ¿¸ÆÁúȯ(CAD) µî ½ÉÇ÷°ü°è Áúȯ¿¡ °É¸®±â ½±±â ¶§¹®¿¡ °í·É ȯÀÚ¿¡¼­ ¾à¹°¿ëÃâ ½ºÅÙÆ®¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¬±¸¿¡ µû¸£¸é, CAD´Â °í·É ¿©¼ºÀÇ ¾à 50%, °í·É ³²¼ºÀÇ 70-80%°¡ ¾Î°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ¿ä¾àÇϸé, ±â¼ú Çõ½ÅÀÇ Áõ°¡¿Í ½ÉÇ÷°üÁúȯÀÇ À¯º´·ü Áõ°¡¿Í °°Àº ¿äÀÎÀº ƯÈ÷ ºÏ¹ÌÀÇ ¾à¹° ¿ëÃâ ½ºÅÙÆ® ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­¸¦ ±¸¸ÅÇØ¾ß ÇÏ´Â ÀÌÀ¯

  • ÅëÂû·Â ÀÖ´Â ºÐ¼® : ÁÖ¿ä Áö¿ª»Ó¸¸ ¾Æ´Ï¶ó ½ÅÈï Áö¿ª, °í°´ ºÎ¹®, Á¤ºÎ Á¤Ã¥ ¹× »çȸ°æÁ¦Àû ¿äÀÎ, ¼ÒºñÀÚ ¼±È£µµ, »ê¾÷º°, ±âŸ ÇÏÀ§ ºÎ¹®¿¡ ÃÊÁ¡À» ¸ÂÃá ½ÉÃþÀûÀÎ ½ÃÀå ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.
  • °æÀï »óȲ : ¼¼°è ÁÖ¿ä ±â¾÷µéÀÌ Ã¤ÅÃÇϰí ÀÖ´Â Àü·«Àû Àü·«À» ÀÌÇØÇϰí, ÀûÀýÇÑ Àü·«À¸·Î ½ÃÀå ħÅõ °¡´É¼ºÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • ½ÃÀå µ¿Çâ°ú ÃËÁø¿äÀÎ : ¿ªµ¿ÀûÀÎ ¿äÀΰú ¸Å¿ì Áß¿äÇÑ ½ÃÀå µ¿Çâ, ±×¸®°í À̵éÀÌ ÇâÈÄ ½ÃÀå ¹ßÀüÀ» ¾î¶»°Ô Çü¼ºÇÒ °ÍÀÎÁö¿¡ ´ëÇØ ¾Ë¾Æº¾´Ï´Ù.
  • ½ÇÇà °¡´ÉÇÑ Á¦¾È : ¿ªµ¿ÀûÀΠȯ°æ ¼Ó¿¡¼­ »õ·Î¿î ºñÁî´Ï½º ½ºÆ®¸²°ú ¼öÀÍÀ» ¹ß±¼Çϱâ À§ÇÑ Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ÀλçÀÌÆ®¸¦ Ȱ¿ëÇÕ´Ï´Ù.
  • ´Ù¾çÇÑ »ç¿ëÀÚ¿¡ ´ëÀÀ : ½ºÅ¸Æ®¾÷, ¿¬±¸±â°ü, ÄÁ¼³ÅÏÆ®, Áß¼Ò±â¾÷, ´ë±â¾÷¿¡ À¯ÀÍÇÏ°í ºñ¿ë È¿À²ÀûÀÔ´Ï´Ù.

¾î¶² ¿ëµµ·Î »ç¿ëµÇ´Â°¡?

»ê¾÷ ¹× ½ÃÀå ÀλçÀÌÆ®, »ç¾÷ ±âȸ Æò°¡, Á¦Ç° ¼ö¿ä ¿¹Ãø, ½ÃÀå ÁøÀÔ Àü·«, Áö¸®Àû È®Àå, ¼³ºñ ÅõÀÚ °áÁ¤, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© ¹× ¿µÇâ, ½ÅÁ¦Ç° °³¹ß, °æÀïÀÇ ¿µÇâ

Á¶»ç ¹üÀ§

  • 2022-2030³â ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø
  • ¼ºÀå ±âȸ, µµÀü°úÁ¦, °ø±Þ¸Á Àü¸Á, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, °í°´ Çൿ, Æ®·»µå ºÐ¼®
  • °æÀï»ç Æ÷Áö¼Å´×, Àü·« ¹× ½ÃÀå Á¡À¯À² ºÐ¼®
  • ºÎ¹® ¹× ±¹°¡¸¦ Æ÷ÇÔÇÑ Áö¿ªº° ¸ÅÃâ ¼ºÀå ¹× ¿¹Ãø ºÐ¼®
  • ±â¾÷ ÇÁ·ÎÆÄÀϸµ(Àü·«, Á¦Ç°, À繫»óÅÂ, ÁÖ¿ä ¹ßÀü µî)

¸ñÂ÷

Á¦1Àå ¼Ò°³

  • ½ÃÀå °³¿ä
  • ½ÃÀå Á¤ÀÇ
  • Á¶»ç ¹üÀ§
  • ½ÃÀå ¼¼ºÐÈ­
  • ÅëÈ­
  • °¡Á¤
  • ±âÁØ ¿¬µµ¿Í ¿¹Ãø ¿¬µµ ŸÀÓ¶óÀÎ
  • ÀÌÇØ°ü°èÀÚ¿¡ ´ëÇÑ ÁÖ¿ä ÀÌÁ¡

Á¦2Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¼³°è
  • Á¶»ç °úÁ¤

Á¦3Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä Á¶»ç °á°ú
  • CXOÀÇ °ßÇØ

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • Porter's Five Forces ºÐ¼®
  • ¾÷°è ¹ë·ùüÀÎ ºÐ¼®
  • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ

Á¦5Àå ¾à¹° ¿ëÃâ ½ºÅÙÆ® ½ÃÀå : ÄÚÆÃ À¯Çüº°

  • ¼Ò°³
  • Æú¸®¸Ó ±â¹Ý ÄÚÆÃ
  • Æú¸®¸Ó ÇÁ¸® ÄÚÆÃ

Á¦6Àå ¾à¹° ¿ëÃâ ½ºÅÙÆ® ½ÃÀå : ¿ëµµº°

  • ¼Ò°³
  • °ü»óµ¿¸ÆÁúȯ(CAD)
  • ¸»Ãʵ¿¸ÆÁúȯ(PAD)

Á¦7Àå ¾à¹° ¿ëÃâ ½ºÅÙÆ® ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¼Ò°³
  • º´¿ø
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±âŸ

Á¦8Àå ¾à¹° ¿ëÃâ ½ºÅÙÆ® ½ÃÀå : Áö¿ªº°

  • ¼Ò°³
  • ºÏ¹Ì
    • ÄÚÆÃ À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾»ç¿ëÀÚº°
    • ±¹°¡º°
  • ³²¹Ì
    • ÄÚÆÃ À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾»ç¿ëÀÚº°
    • ±¹°¡º°
  • À¯·´
    • ÄÚÆÃ À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾»ç¿ëÀÚº°
    • ±¹°¡º°
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ÄÚÆÃ À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾»ç¿ëÀÚº°
    • ±¹°¡º°
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÄÚÆÃ À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾»ç¿ëÀÚº°
    • ±¹°¡º°

Á¦9Àå °æÀï ȯ°æ°ú ºÐ¼®

  • ÁÖ¿ä ±â¾÷°ú Àü·« ºÐ¼®
  • ½ÃÀå Á¡À¯À² ºÐ¼®
  • ÇÕº´, Àμö, ÇÕÀÇ, Çù¾÷
  • °æÀï ´ë½Ãº¸µå

Á¦10Àå ±â¾÷ °³¿ä

  • Abbott Cardiovascular
  • Boston Scientific Corporation
  • Medtronic Plc
  • Biotronik
  • Terumo Corporation
  • MicroPort Scientific Corporation
  • Biosensors International
  • Alvimedica
  • Lepu Medical Technology
  • MedicalExpo
  • Cook Medical
  • B. Braun
  • Biotronik
  • MicroPort Scientific Corporation
  • Sahajanand Medical Technologies
ksm 25.02.27

The Drug eluting stent market is projected to grow at a CAGR of 8.20% over the forecast period, increasing from US$11.499 billion in 2025 to US$17.049 billion by 2030.

A drug-eluting stent is a metallic, semi-rigid tubular device that has a drug attached to it, allowing for a slow release of medication to prevent the recurrence of stenosis or arterial obstruction. Recent innovations in stent designs and delivery technologies are expected to significantly reduce the restenosis rate, even in complex lesions, thereby decreasing the incidence of both early and late thrombosis. The growing geriatric population worldwide is a major driver for the drug-eluting stent market, as the likelihood of developing vascular diseases increases with age, leading to greater demand for effective treatment options like drug-eluting stents. Additionally, sedentary lifestyles and poor dietary habits are contributing to a rise in cases of atherosclerosis, characterized by plaque buildup in the arteries.

Drivers of the Drug-Eluting Stent Market

  • Technological Advancements: The transition from standard angioplasty to drug-eluting stents (DES) represents a significant advancement in treatment options. By integrating medication therapy directly onto the stent, this minimally invasive approach offers numerous benefits, including reduced stress on blood vessels, faster recovery times, and lower complication risks. For example, the Orsiro Mission represents a technological breakthrough that delivers drugs directly into target arteries, thereby improving patient outcomes. The successful implementation of such innovative solutions is likely to increase market activity as healthcare professionals seek more effective and less invasive treatments for arterial disorders.

Geographical Outlook

  • North America Expected to Lead: North America is projected to hold a substantial share of the drug-eluting stent market during the forecast period. This growth can be attributed to favorable reimbursement policies and a rising incidence of artery-related diseases in the region. Furthermore, advancements in drug-eluting stent technology and a robust healthcare infrastructure have contributed to market expansion. According to the Journal of the American College of Cardiology published in February 2023, the incidence rate of atherosclerotic cardiovascular disease in the United States was 2.60 per 1,000 person-years among individuals with high 10-year predicted risk. This statistic underscores the growing need for effective treatment options like drug-eluting stents.

As the aging population is more susceptible to cardiovascular diseases such as coronary artery disease (CAD), there is an increasing demand for drug-eluting stents among older patients. Studies indicate that CAD affects approximately 50% of older women and 70%-80% of older men. Additionally, Canada's elderly population is projected to grow significantly over the next two decades, further driving demand for these medical devices.In summary, factors such as rising technological innovations and an increasing prevalence of cardiovascular diseases are expected to propel growth in the drug-eluting stent market, particularly in North America.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Drug eluting stent market is segmented and analyzed as follows:

By Coating Type

  • Polymer-Based Coating
  • Polymer-Free Coating.

By Application

  • Coronary Artery Disease (CAD)
  • Peripheral Artery Disease (PAD)

By End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • UK
  • France
  • Spain
  • Others
  • Middle East and Africa
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Taiwan
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. DRUG ELUTING STENT MARKET BY COATING TYPE

  • 5.1. Introduction
  • 5.2. Polymer-Based Coating
  • 5.3. Polymer-Free Coating

6. DRUG ELUTING STENT MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Coronary Artery Disease (CAD
  • 6.3. Peripheral Artery Disease (PAD)

7. DRUG ELUTING STENT MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Ambulatory Surgical Centers
  • 7.4. Others

8. DRUG ELUTING STENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Coating Type
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Coating Type
    • 8.3.2. By Application
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Coating Type
    • 8.4.2. By Application
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. Germany
      • 8.4.4.2. UK
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Coating Type
    • 8.5.2. By Application
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. UAE
      • 8.5.4.2. Israel
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Coating Type
    • 8.6.2. By Application
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. South Korea
      • 8.6.4.4. India
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Taiwan
      • 8.6.4.7. Thailand
      • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Abbott Cardiovascular
  • 10.2. Boston Scientific Corporation
  • 10.3. Medtronic Plc
  • 10.4. Biotronik
  • 10.5. Terumo Corporation
  • 10.6. MicroPort Scientific Corporation
  • 10.7. Biosensors International
  • 10.8. Alvimedica
  • 10.9. Lepu Medical Technology
  • 10.10. MedicalExpo
  • 10.11. Cook Medical
  • 10.12. B. Braun
  • 10.13. Biotronik
  • 10.14. MicroPort Scientific Corporation
  • 10.15. Sahajanand Medical Technologies
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦